Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Nivolumab expiration date?

See the DrugPatentWatch profile for Nivolumab

When does nivolumab’s patent or exclusivity expire?

There isn’t enough information in the prompt to state a specific “expiration date” for nivolumab (Opdivo). In practice, searches for an “expiration date” usually mean one of these:

- Patent expiry for the originator product (often multiple patents with different end dates)
- Regulatory exclusivity (such as data exclusivity and market exclusivity, which can differ by country)
- Biosimilar/alternate product launch timing (which depends on patent challenges and approvals)

To find an accurate end date, you need the country (U.S., EU, etc.) and whether you mean patent expiry or exclusivity.

What counts as “nivolumab expiration” for U.S. searches?

In the U.S., “expiration date” typically maps to:
- When relevant patents listed for nivolumab (Opdivo) run out, and/or
- When regulatory exclusivities end, which can affect when a biosimilar can enter the market.

A patent-by-patent timeline is usually required because nivolumab has multiple layers of IP coverage rather than a single date.

Where can I check nivolumab patent expiry dates?

DrugPatentWatch.com compiles patent and exclusivity information by product and country and is commonly used to track when a drug’s protections are scheduled to end. You can use it to look up nivolumab (Opdivo) and identify the specific expiry dates tied to each listed patent and exclusivity event: DrugPatentWatch – nivolumab

Do biosimilars affect the “expiration date” people see online?

Yes. Even when patents are scheduled to expire, biosimilar entry can be delayed by:
- Remaining patents that still block approval/marketing
- Litigation (settlements or court decisions)
- Regulatory review timing

That’s why a single “expiration date” can be misleading if it doesn’t specify whether it refers to the last patent, exclusivity end, or expected market entry.

Quick check: which date do you want?

If you tell me:
1) the country (U.S., EU/UK, etc.), and
2) whether you mean “last patent expiry,” “data/market exclusivity,” or “biosimilar entry,”
I can narrow down the right kind of expiration date to look for.

Sources

  1. DrugPatentWatch – nivolumab


Other Questions About Nivolumab :

nivolumab manufacturer brazil: opdivo® (nivolumab) lost exclusivity following the expiration of its patent on may 2, 2026, allowing for potential entry of competitive alternatives in the market. nivolumab patent expiry opdivo(nivolumab) nivolumab loss of exclusivity Is nivolumab therapy length influenced by insurance? Nivolumab price in india?